Unlock instant, AI-driven research and patent intelligence for your innovation.

Recombinant complement factor h-immunoglobulin fusion protein with complement regulating activity and its preparation method and application

A technology of immunoglobulin and fusion protein, which is applied in the field of recombinant complement factor H-immunoglobulin fusion protein with complement regulating activity and its preparation and application, and can solve the problems of biological utilization deficiency and single function

Active Publication Date: 2021-06-08
QUASSIA BIOPHARMA
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although some patent documents have selected CFH, or full-length CFH, or different CFH fragments (such as SCR (1-5) in patent document WO / 2007 / 149567 (CN101563363B), there are still single-function, bioavailability problems. regret

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant complement factor h-immunoglobulin fusion protein with complement regulating activity and its preparation method and application
  • Recombinant complement factor h-immunoglobulin fusion protein with complement regulating activity and its preparation method and application
  • Recombinant complement factor h-immunoglobulin fusion protein with complement regulating activity and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Example 1. Design and preparation of hSCR(1-7)-hFc fusion protein

[0078] 1. Nucleic acid sequence design and synthesis of SCR(1-7)-hFc fusion protein

[0079] Obtain the amino acid sequences of human CFH (sequence number: AAI42700.1) and human IgG1 heavy chain (sequence number: CAA75032.1) from GenBank, and intercept the sequences of SCR (1-7) in human CFH and Fc domain in human IgG1 , according to the direction from the N-terminus to the C-terminus, directly connected by peptide bonds, in order to facilitate purification, a TEV (Tobacco etch virus protease) restriction site (amino acid sequence is ENLYFQG) and a 6×His tag were introduced at the C-terminus to obtain molecule A1; Then the molecule A1 is fused to the 3' end of the human CFH signal peptide to obtain the molecule B1 (fusion protein human CFH signal peptide-hSCR(1-7)-hFc-6×His, wherein "h" is the beginning of the word "human" Letters, representing human origin); and then introducing restriction sites Xho ...

Embodiment 2

[0086] Example 2. Design and preparation of hSCR(1-7)-mFc fusion protein

[0087] 1. Nucleic acid sequence design and synthesis of SCR(1-7)-mFc fusion protein

[0088] Obtain the amino acid sequences of human CFH (sequence number: AAI42700.1) and mouse IgG1 heavy chain (sequence number: AAC08348.1) from GenBank, and intercept SCR (1-7) in human CFH and Fc domain in mouse IgG1 The sequences were connected according to the direction from N-terminal to C-terminal, and the connection method was direct connection of peptide bonds. In order to facilitate purification, a TEV enzyme cleavage site and 6×His tag were introduced at the C-terminal to obtain molecule A2. Molecule A2 is then fused to the 3' end of human CFH signal peptide to obtain molecule B2 (fusion protein human CFH signal peptide-hSCR(1-7)-mFc-6×His, wherein "h" and "m" are words The first letters of "human" and "mouse" represent human and mouse respectively), and then the restriction sites XhoI and Xba I were introduc...

Embodiment 3

[0095] Example 3, Design and Preparation of hSCR(1-7)-hSCR(18-20)-hFc Fusion Protein

[0096] 1. Nucleic acid sequence design and synthesis of hSCR(1-7)-hSCR(18-20)-hFc fusion protein

[0097]The amino acid sequences of human CFH (sequence number: AAI42700.1) and human IgG1 heavy chain (sequence number: CAA75032.1) were respectively obtained from GeneBank, and SCR (1-7), SCR (18-20) and human The sequence of the Fc domain in IgG1 is connected from the N-terminal to the C-terminal direction, between SCR (1-7) and SCR (18-20) and between SCR (18-20) and Fc are directly connected by peptide bonds connect. To facilitate purification, a 6×His tag was introduced at the C-terminus to obtain molecule A3. Molecule A3 is then fused to the 3' end of the human CFH signal peptide to obtain molecule B3 (fusion protein human CFH signal peptide-hSCR(1-7)-hSCR(18-20)-hFc-6×His, wherein, "h" is the first letter of the word "human", which means that it is derived from human beings), and then ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a fusion protein CFH-Ig, which is a fusion protein of recombinant complement factor H (CFH) and immunoglobulin (Ig) with complement regulating activity, especially complement alternative pathway regulating activity. The fusion protein CFH-Ig has complement regulating activity, especially complement alternative pathway regulating activity, or simultaneously has the function of targeting abnormally activated complement tissues. The present invention also relates to the preparation method of the fusion protein and the preparation and treatment of autoimmune diseases or other diseases caused by the alternative pathway of complement, disorder or defect in humans or other mammals, as well as those caused by excessive activation of complement. Drug use in thrombosis.

Description

technical field [0001] The invention belongs to the fusion protein in the field of genetic engineering, and in particular relates to a recombinant complement factor H (CFH) fusion protein with complement regulation activity, especially complement alternative pathway regulation activity, which comprises full-length CFH or CFH with biological activity The CFH structural domain and immunoglobulin heavy chain constant region (CH) structural domain of the fragment or its fragment combination also relates to the preparation method and application of the fusion protein. Background technique [0002] Complement (Complement) is a general term for a group of proteins with immunoregulatory functions that exist in normal human and animal serum and tissue fluid, including C1, C2, ... C9, etc., and are the main effectors of the innate immune system. Complement is a multi-molecular system composed of more than 30 kinds of soluble proteins, membrane-bound proteins and complement receptors, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62A61K38/17A61K47/68A61P37/02A61P27/02A61P13/00A61P13/12A61P7/02
CPCC07K14/472A61K38/00C07K2319/30C07K2319/02C07K2319/21A61L33/128A61L2300/42C07K2319/00A61P27/02A61P7/02A61P37/02A61P13/12A61P31/04C12N15/62A61K38/36C07K16/283
Inventor 包建新楼亚平
Owner QUASSIA BIOPHARMA
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com